Livtencity™ (maribavir) – New orphan drug approval
November 23, 2021 - Takeda announced the FDA approval of Livtencity (maribavir), for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.
Top